Zogenix Appoints New Chief Commercial Officer

Zogenix Appoints New Chief Commercial Officer

SAN DIEGO, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain, today announced the
appointment of R. Scott Shively to serve as executive vice president and chief
commercial officer. Scott previously served as vice president - global
commercial disease area lead for pain for Pfizer, Inc. Scott will be
responsible for all of Zogenix's commercial strategies and operations
including the currently marketed product, SUMAVEL^® DosePro^®, and the
anticipated launch of the company's product candidate, Zohydro^TM ER
(hydrocodone bitartrate extended release capsules) which is pending FDA
approval. In addition he will be a key member of the executive leadership team
focused on strategic direction, product in-licensing, co-development
opportunities and the established co-promotion with Covidien.

Scott has over 30 years of pharmaceutical industry experience in a variety of
sales and marketing leadership positions including responsibility for early
stage programs and an impressive list of successfully commercialized products,
with extensive experience in pain. In his most recent role at Pfizer, Scott
had global commercial leadership responsibility for Pfizer's primary care pain
franchise including products such as Lyrica, Celebrex and Embeda, as well as
for all pain pipeline products, and was the lead interface for Pfizer's Pain
discovery research unit. Also while at Pfizer, Scott was heavily involved in
the establishment and potential business expansion of Pfizer's new Integrated
Health Business Unit. Prior to Pfizer, Scott was senior vice president for
commercial operations at Alpharma Pharmaceuticals, a specialty pharmaceutical
company focused on pain management.As senior vice president for global
respiratory as well as interim president and chief executive officer, USA at
Altana AG, Scott was responsible for the company's U.S. operations, including
a sales force of over 500 representatives. Previous to that, Scott had a
variety of sales, marketing and international and domestic commercial
leadership roles at subsidiaries of Sanofi-Aventis for nearly 20 years. Scott
holds a B.S. in Zoology from Duke University with a pre-medical focus.

"Because of his extensive experience in building commercial organizations,
successful brands and companies of all sizes, Scott is the ideal choice to
join our Zogenix executive leadership team at this critical and exciting time.
We have the potential of launching a new product, expanding our commercial
organization and pursuing a range of corporate development opportunities,"
said Roger Hawley, chief executive officer of Zogenix. "Scott's commercial
expertise will add important depth and breadth to our executive team. He
understands our vision as well as the challenges and opportunities we face.
Scott's experience with pain therapeutics will add keen insights into a
complex market including vital compliance and safe-use requirements for the

Scott Shively said, "The milestones Zogenix has already achieved in just 6
years are impressive. The portfolio, the DosePro platform and the commercial
organization's growth potential, which are supported by a high-quality team
with an experienced board of directors, all attracted me to Zogenix. I believe
my experience, not only in the pain market but also with partnering
opportunities and successfully building brands, will provide benefits now and
into the next phase of the company's growth. It's an exciting time to join and
to make a contribution to the ongoing success of Zogenix."

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a
pharmaceutical company commercializing and developing products for the
treatment of central nervous system disorders and pain. Zogenix's first
commercial product, SUMAVEL^® DosePro^® (sumatriptan injection) Needle-free
Delivery System, was launched in January 2010 for the acute treatment of
migraine and cluster headache. Zogenix's lead investigational product
candidate, Zohydro^TM ER (hydrocodone bitartrate) is an oral, novel
extended-release formulation of various strengths of hydrocodone without
acetaminophen intended for administration every 12 hours for around the clock
management of moderate to severe chronic pain. Zogenix's second DosePro
investigational product candidate, Relday^TM, is a proprietary, long-acting
injectable formulation of risperidone for the treatment of schizophrenia. In
May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER
and an Investigational New Drug Application for Relday. The FDA assigned a
PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ^®, DosePro ^®, Relday^TM and Zohydro^TM ER are trademarks of Zogenix,

         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
         Victoria Aguiar | The Ruth Group
         646.536.7013 | vaguiar@theruthgroup.com
Press spacebar to pause and continue. Press esc to stop.